Aqr Capital Management LLC Aldeyra Therapeutics, Inc. Transaction History

Aqr Capital Management LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$3.25 - $4.72 $228,387 - $331,688	-70,273 Reduced 66.89%	34,781 $115,000
Q1 2024 May 15, 2024	BUY	$2.77 - $4.22 $290,999 - $443,327	105,054 New	105,054 $343,000
Q3 2023 Nov 14, 2023	SELL	$6.11 - $8.16 $32,046 - $42,799	-5,245 Reduced 20.05%	20,913 $139,000
Q2 2023 Aug 14, 2023	BUY	$7.11 - $11.89 $185,983 - $311,018	26,158 New	26,158 $219,000
Q2 2022 Aug 15, 2022	BUY	$2.43 - $4.85 $99,518 - $198,626	40,954 New	40,954 $163,000
Q3 2021 Nov 15, 2021	SELL	$7.94 - $11.31 $179,674 - $255,933	-22,629 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$10.44 - $14.85 $236,246 - $336,040	22,629 New	22,629 $256,000
Q2 2019 Aug 14, 2019	SELL	$6.0 - $9.0 $120,870 - $181,305	-20,145 Closed	0 $0
Q1 2019 May 14, 2019	BUY	$7.14 - $9.85 $51,200 - $70,634	7,171 Added 55.27%	20,145 $182,000
Q4 2018 Feb 14, 2019	BUY	$7.26 - $13.29 $94,191 - $172,424	12,974 New	12,974 $108,000

117

36.4M

196K

142K

Ticker ALDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,323,100
Market Cap $279M
Description
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...

Get notified when there are updates to the investment portfolio of Aqr Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Aqr Capital Management LLC with notifications on news.